3rd Quarter - Report

ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.

Period 3rd Quarter 2012 Filed Oct 22, 2012 Signed by Mary-Lacey Reuther, Director of Federal and External Affairs

Official filing
Firm
ASTELLAS PHARMA US, INC.
Client
ASTELLAS PHARMA US, INC.
Income
—
Expenses
$560,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
RYAN AMBROSE House Committee on Energy & Commerce, Clerk
MARY LACEY REUTHER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5358 (112th), H.R. 5357 (112th), H.R. 5359 (112th), H.R. 5364 (112th), H.R. 5345 (112th)

Health Issues HCR

Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to implementation of the Prescription Drug User Fee Act (now Public Law 112-144)

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
RYAN AMBROSE House Committee on Energy & Commerce, Clerk
MARY LACEY REUTHER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1734 (112th), H.R. 2182 (112th)

Medicare/Medicaid MMM

Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
RYAN AMBROSE House Committee on Energy & Commerce, Clerk
MARY LACEY REUTHER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2969 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.